Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre

Wang, Xin; Waldman, Larissa; Silberman, Yael; Wang, Michael; Tackey, Caleb; Hanna, Lilian; Vesprini, Danny; Emmenegger, Urban; Eisen, Andrea; Smoragiewicz, Martin

doi:10.1016/j.clgc.2024.02.003

Clinical Genitourinary Cancer

2024

DOI: 10.1016/j.clgc.2024.02.003

|View full text |Cite

Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre

Xin Wang,

Larissa Waldman,

Yael Silberman

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The Efforts to Prevent Cancer Genetic Testing are Coming to an End

Hughes,

Euhus

2024

Ann Surg Oncol

View full text Add to dashboard Cite

When cancer genetic testing was introduced in the 1990s, a great deal was unknown about cancer risk assessment and risk management. Consequently, genetics professionals supported strict guidelines to protect patients from physical, psychological, and financial harm. The ensuing decades witnessed significant advancements in knowledge and practice, but the guidelines remained entrenched, creating the impression that cancer genetic testing is difficult, is dangerous for the patients, and should not be done by anyone but trained genetics professionals. The result has been that the vast majority of patients with cancer-causing pathogenic variants remain unidentified and continue to develop cancers that could have been prevented or found earlier. We can get a sense of the scale of this problem by considering a few of the major cancers for which cancer genetic testing is available. Of the 600,000 breast, ovarian, colorectal, and endometrial cancers diagnosed each year, approximately 60,000 (10%) are likely caused by an identifiable pathogenic variant in a cancer predisposition gene. 1 The vast majority of these patients are never tested, which denies them the opportunity for diagnosis at an earlier stage or prevention of their cancer altogether. During the past 10 years, approximately 600,000 patients, mostly women, have been poorly served.This article refers to: Shim V, Karlea A, Brenman LM, et al. Mainstream germline genetic testing with expanded eligibility for early breast cancer patients in a large integrated health system.

show abstract

The Efforts to Prevent Cancer Genetic Testing are Coming to an End

Hughes,

Euhus

2024

Ann Surg Oncol

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre

Cited by 1 publication

References 26 publications

The Efforts to Prevent Cancer Genetic Testing are Coming to an End

The Efforts to Prevent Cancer Genetic Testing are Coming to an End

Contact Info

Product

Resources

About